These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 30316363)

  • 21. Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes.
    Wiebe C; Pochinco D; Blydt-Hansen TD; Ho J; Birk PE; Karpinski M; Goldberg A; Storsley LJ; Gibson IW; Rush DN; Nickerson PW
    Am J Transplant; 2013 Dec; 13(12):3114-22. PubMed ID: 24164958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eplet matching in pediatric heart transplantation: The SickKids experience.
    Cardoso B; Wang J; Kiernan J; Dipchand AI
    J Heart Lung Transplant; 2022 Oct; 41(10):1470-1477. PubMed ID: 35933296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epitope analysis of HLA-DQ antigens: what does the antibody see?
    Tambur AR; Rosati J; Roitberg S; Glotz D; Friedewald JJ; Leventhal JR
    Transplantation; 2014 Jul; 98(2):157-66. PubMed ID: 25003284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is the level of HLA eplet mismatch a risk factor for graft loss among kidney transplant recipients who have already formed de novo donor specific antibody?
    Wen J; Basu A; Bentall A; Henderson N; Dukek B; Gandhi M; Schinstock C
    Hum Immunol; 2021 Apr; 82(4):240-246. PubMed ID: 33618904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HLA-DQ eplet mismatch load may identify kidney transplant patients eligible for tacrolimus withdrawal without donor-specific antibody formation after mesenchymal stromal cell therapy.
    Bezstarosti S; Meziyerh S; Reinders MEJ; Voogt-Bakker K; Groeneweg KE; Roelen DL; Kers J; de Fijter JW; Heidt S
    HLA; 2023 Jul; 102(1):3-12. PubMed ID: 36841928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Immunogenicity of HLA Class II Mismatches: The Predicted Presentation of Nonself Allo-HLA-Derived Peptide by the HLA-DR Phenotype of the Recipient Is Associated with the Formation of DSA.
    Jucaud V
    J Immunol Res; 2017; 2017():2748614. PubMed ID: 28331856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Accuracy of Sequence-Specific Oligonucleotide and Real-Time Polymerase Chain Reaction HLA Typing in Determining the Presence of Pre-Transplant Donor-Specific Anti-HLA Antibodies and Total Eplet Mismatches for Deceased Donor Kidney Transplantation.
    Larkins NG; D'Orsogna L; Taverniti A; Sharma A; Chakera A; Chan D; Krishnan A; Wong G; Lim WH
    Front Immunol; 2022; 13():844438. PubMed ID: 35799779
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicted indirectly recognizable HLA epitopes presented by HLA-DR correlate with the de novo development of donor-specific HLA IgG antibodies after kidney transplantation.
    Otten HG; Calis JJ; Keşmir C; van Zuilen AD; Spierings E
    Hum Immunol; 2013 Mar; 74(3):290-6. PubMed ID: 23232063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eplet mismatches associated with de novo donor-specific HLA antibody in pediatric kidney transplant recipients.
    Charnaya O; Jones J; Philogene MC; Chiang PY; Segev DL; Massie AB; Garonzik-Wang J
    Pediatr Nephrol; 2021 Dec; 36(12):3971-3979. PubMed ID: 34100108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted monitoring of donor-specific HLA antibodies following renal transplantation.
    Almeshari K; Pall A; Chaballout A; Elgamal H; Almana H; Alzayer F; Abaalkhail N; Altalhi M
    Clin Transpl; 2011; ():395-400. PubMed ID: 22755437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HLA-C antibodies are associated with irreversible rejection in kidney transplantation: Shared molecular eplets characterization.
    Bosch A; Llorente S; Eguia J; Mrowiec A; Boix F; López-Hernández R; Campillo JA; Salgado G; Moya-Quiles MR; Minguela A; Jimeno L; Alvarez-López MR; Muro M
    Hum Immunol; 2014 Apr; 75(4):338-41. PubMed ID: 24486575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of HLA B- and T-cell molecular mismatches with HLA antibodies, rejection, and graft survival in pediatric kidney transplantation.
    Gramkow AM; Baatrup JH; Gramkow ET; Thiesson HC; Koefoed-Nielsen P
    Pediatr Transplant; 2024 Aug; 28(5):e14773. PubMed ID: 38808702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of active antibody-mediated rejection treatment on donor-specific antibodies in pediatric kidney transplant recipients.
    Kincaide E; Hitchman K; Hall R; Yamaguchi I; Ding Y; Crowther B
    Pediatr Transplant; 2019 Dec; 23(8):e13590. PubMed ID: 31617318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Donor-specific antibodies, glomerulitis, and human leukocyte antigen B eplet mismatch are risk factors for peritubular capillary C4d deposition in renal allografts.
    Zheng J; Guo H; Gong HL; Lan P; Ding CG; Li Y; Ding XM; Xue WJ
    Chin Med J (Engl); 2021 Oct; 134(23):2874-2881. PubMed ID: 34711716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of HLA eplet mismatch load in immunological outcomes after living donor kidney transplantation.
    Alves TA; Nascimento E; de Castro LB; Fabreti-Oliveira RA
    Transpl Immunol; 2023 Oct; 80():101908. PubMed ID: 37536379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urinary CXCL10 specifically relates to HLA-DQ eplet mismatch load in kidney transplant recipients.
    San Segundo D; Guiral-Foz SA; Benito-Hernández A; Fernández AR; Arnau A; Valero R; Ramos-Barrón MA; García-Unzueta MT; Gómez-Ortega JM; López-Hoyos M; Ruiz JC; Rodrigo E
    Transpl Immunol; 2022 Feb; 70():101494. PubMed ID: 34774739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eplet mismatch scores and de novo donor-specific antibody development in simultaneous pancreas-kidney transplantation.
    Ladowski JM; Mullins H; Romine M; Kloda D; Young C; Hauptfeld-Dolejsek V; Houp J; Locke J
    Hum Immunol; 2021 Mar; 82(3):139-146. PubMed ID: 33390268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HLA-DR and -DQ eplet mismatches and transplant glomerulopathy: a nested case-control study.
    Sapir-Pichhadze R; Tinckam K; Quach K; Logan AG; Laupacis A; John R; Beyene J; Kim SJ
    Am J Transplant; 2015 Jan; 15(1):137-48. PubMed ID: 25521856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody-Mediated Rejection in Kidney Transplantation Without Evidence of Anti-HLA Antibodies?
    Irure J; López-Hoyos M; Rodrigo E; Gómez-Román J; Ruiz JC; Arias M; San Segundo D
    Transplant Proc; 2016 Nov; 48(9):2888-2890. PubMed ID: 27932099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients.
    Lee H; Han E; Choi AR; Ban TH; Chung BH; Yang CW; Choi YJ; Oh EJ
    PLoS One; 2018; 13(11):e0207434. PubMed ID: 30427941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.